Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation

被引：0

作者：

Kuroiwa, Kai ^{[1
]}

Sato, Misuzu ^{[2
]}

Narita, Hinako ^{[1
]}

Okamura, Reiko ^{[1
]}

Uesugi, Yuka ^{[1
]}

Sasaki, Yohei ^{[1
]}

Shimada, Shotaro ^{[1
]}

Watanuki, Megumi ^{[1
]}

Fujiwara, Shun ^{[1
]}

Kawaguchi, Yukiko ^{[1
]}

Arai, Nana ^{[1
]}

Yanagisawa, Kouji ^{[1
]}

Iezumi, Keiichi ^{[2
]}

Hattori, Norimichi ^{[1
]}

机构：

[1] Showa Univ, Sch Med, Dept Med, Div Hematol,Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan

[2] Showa Univ, Sch Med, Dept Pathol & Lab Med, Tokyo, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2024年 / 119卷 / 05期

关键词：

Allogeneic hematopoietic stem cell transplantation; FOXP3; Polymorphism; Graft-versus-host disease; VERSUS-HOST-DISEASE; REGULATORY T-CELLS; ASSOCIATION; IMBALANCE; INDEX;

D O I：

10.1007/s12185-024-03726-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The impact of FOXP3 single-nucleotide polymorphisms (SNP) on clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains poorly understood. We investigated the relationship between a FOXP3 SNP (rs3761548) and clinical outcomes in 91 patients with hematological malignancies after allo-HSCT. Multivariate analysis showed that risk of severe chronic graft-versus-host disease (cGVHD) was significantly higher in patients with the FOXP3-3279C/A or FOXP3-3279A/A genotype than those with the FOXP3-3279C/C genotype [hazard ratio (HR), 2.69; 95% confidence interval (CI) 1.14-6.31; p = 0.023]. Therefore, FOXP3 at SNP rs3761548 can be a useful marker for predicting the occurrence of severe cGVHD.

引用

页码：583 / 591

页数：9

共 50 条

[31] Diabetes Mellitus after Allogeneic Hematopoietic Stem Cell Transplantation
Wedrychowicz, Anna
Ciechanowska, Marta
Stelmach, Malgorzata
Starzyk, Jerzy
HORMONE RESEARCH IN PAEDIATRICS, 2013, 79 (01): : 44 - 50
[32] Bronchial Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
Bergeron, A.
Godet, C.
Chevret, S.
Lorillon, G.
de Latour, R. Peffault
Robin, M.
Ribaud, P.
Socie, G.
Tazi, A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
[33] Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation
Kato, Keisuke
Koike, Kazutoshi
Kobayashi, Chie
Iijima, Shigeruko
Hashimoto, Takashi
Tsuchida, Masahiro
PEDIATRICS INTERNATIONAL, 2015, 57 (03) : 480 - 483
[34] Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
Yingxue Lu
Xiaojing Ma
Jie Pan
Rongqiang Ma
Yujie Jiang
Lipids in Health and Disease, 21
[35] Graft failure after allogeneic hematopoietic stem cell transplantation
Ozdemir, Zehra Narli
Bozdag, Sinem Civriz
TRANSFUSION AND APHERESIS SCIENCE, 2018, 57 (02) : 163 - 167
[36] Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation
Agteresch, H. J.
Veer, M. B. van 't
Cornelissen, J. J.
Sluiters, J. F.
BONE MARROW TRANSPLANTATION, 2007, 40 (04) : 391 - 393
[37] Immune Reconstitutional after Allogeneic Hematopoietic Stem Cell Transplantation
Ogonek, Justyna
Juric, Mateja Kralj
Ghimire, Sakhila
Varanasi, Pavankumar Reddy
Holler, Ernst
Greinix, Hildegard
Weissinger, Eva
FRONTIERS IN IMMUNOLOGY, 2016, 7
[38] ABO antibodies after allogeneic hematopoietic stem cell transplantation
Stussi, G
Huggel, K
Schanz, U
Halter, J
Passweg, J
Gratwohl, A
Seebach, JD
BONE MARROW TRANSPLANTATION, 2003, 31 : S114 - S114
[39] Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation
Lu, Yingxue
Ma, Xiaojing
Pan, Jie
Ma, Rongqiang
Jiang, Yujie
LIPIDS IN HEALTH AND DISEASE, 2022, 21 (01)
[40] Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
Williams, Kirsten M.
Chien, Jason W.
Gladwin, Mark T.
Pavletic, Steven Z.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (03): : 306 - 314

← 1 2 3 4 5 →